Welcome to the 3rd Global XDC Innovation Conference

With more than 20 mergers, acquisitions and licensing/partnership deals in 2023, there has never been a stronger time for antibody drug conjugates (ADCs) and novel bioconjugates.  More than 200 ADCs are in the clinical development stage globally based on the data from Frost & Sullivan, PharmNoteas of Dec 2023.  The number of new clinical ADC targets has also reached an all-time high. Besides the traditional clinically validated targets such as HER2 and TROP2, novel targets such as HER3, Claudin 18.2, EGFR have also shown inspiring efficacy in clinics.

As the year 2024 has been considered the ‘coming of age’ era for ADC, the 3rd Global XDC Innovation Conference is coming back this September in WuXi, China, hosted by WuXi XDC and BioValley.  With the theme of Explore the Unlimited Potentials of Bioconjugates, the conference will focus on novel targets identification and validation, recent innovations in ADC and bioconjugation, potential payload-linker technologies that are changing the target selection paradigm and ushering in a new era of ADC field, as well as pressing challenges in CMC and commercialization.

We look forward to welcoming the global ADC and bioconjugate community back to Wuxi City this September for a melting pot of innovation, collaboration, and inspiration that can propel the ADC and bioconjugate development further than ever before!